IP Library › Granted Patent US 11,512,283
Granted Patent B2
US 11,512,283 · App. 16/454,168 · Granted Nov 29, 2022

Media for culturing stem cells

Inventors: Michal Amit (Yuvalim, IL); Joseph Itskovitz-Eldor (Haifa, IL)
Assignee: Technion Research & Development Foundation Limited
C12N5/0606C12N5/0018C12N5/0037C12N5/0043C12N5/0056C12N5/0602C12N5/0603C12N2500/90C12N2500/98C12N2501/115C12N2501/15C12N2501/23C12N2501/2306C12N2506/02C12N2533/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,512,283
App. No.
16/454,168
Granted
Nov 29, 2022
Kind
B2
Abstract

Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.

Claims (21)

1. A culture medium comprising an IL6RIL6 chimera, basic fibroblast growth factor (bFGF) and ascorbic acid, wherein said IL6RIL6 chimera comprises amino acids 112-355 of SEQ ID NO: 32, wherein said culture medium is capable of maintaining said human pluripotent stem cell in an undifferentiated state for at least 7 passages.

2. The culture medium of claim 1 , wherein said IL6RIL6 chimera is provided at a concentration of at least 25 ng/ml.

3. The culture medium of claim 1 , wherein said IL6RIL6 chimera is provided at a concentration of at least 200 ng/ml.

4. The culture medium of claim 1 , wherein said culture medium is serum replacement-free.

5. The culture medium of claim 1 , wherein said culture medium comprises serum replacement.

6. The culture medium of claim 1 , wherein said culture medium is devoid of animal contaminant.

7. A cell culture comprising a human pluripotent stem cell and the culture medium of claim 1 .

8. The cell culture of claim 7 , wherein said IL6RIL6 chimera is provided at a concentration of at least 25 ng/ml.

9. The cell culture of claim 7 , wherein said IL6RIL6 chimera is provided at a concentration of at least 200 ng/ml.

10. The cell culture of claim 7 , wherein said culture medium comprises serum or serum replacement.

11. The cell culture of claim 7 , wherein said culture medium is serum replacement-free.

12. The cell culture of claim 7 , wherein said culture medium is devoid of animal contaminant.

13. The cell culture of claim 7 , wherein the human pluripotent stem cell is a human embryonic stem cell.

14. A method of deriving a human embryonic stem cell line, the method comprising:

(a) obtaining a human embryonic stem cell from a pre-implantation stage blastocyst, post-implantation stage blastocyst and/or a genital tissue of a fetus; and

(b) culturing said human embryonic stem cell in the culture medium of claim 1 , thereby deriving the embryonic stem cell line.

15. The culture medium of claim 1 , wherein said ascorbic acid is at a concentration of 500 ng/ml ±10%.

16. A defined culture medium devoid of animal contaminants wherein the medium comprises an IL6RIL6 chimera, basic fibroblast growth factor (bFGF), ascorbic acid, insulin, transferrin, selenium and a lipid mixture, wherein said IL6RIL6 chimera comprises amino acids 112-355 of SEQ ID NO: 32, wherein said culture medium is capable of maintaining said human pluripotent stem cell in an undifferentiated state for at least 7 passages.

17. The medium of claim 16 , wherein said bFGF is at a concentration of at least 2 ng/ml bFGF.

18. The medium of claim 16 , wherein said ascorbic acid is at a concentration of 500 ng/ml ±10%.

19. The medium of claim 16 , wherein said IL6RIL6 chimera is at a concentration of at least 25 ng/ml.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2019
From: AMIT, MICHAL; ITSKOVITZ-ELDOR, JOSEPH
To: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
Reel/Frame 049746/0697 →
Continuity (6)
Division 15209776 · Jul 14, 2016
Continuation 13909128 · Jun 4, 2013
Division 11991077
Provisional Application 60834795 · Aug 2, 2006
Provisional Application 60711668 · Aug 29, 2005
Related Publication 20190316082A1 · Oct 17, 2019